CNR1 and Hepatic fibrosis: In contrast, genetic and pharmacological inactivation of CB1 with rimonabant enhances HSC apoptosis and decreases the proliferative response to platelet-derived growth factor (PDGF), reducing TGFβ1 levels and liver fibrosis [92].